nach oben

Erschienen in:

18.06.2020 | Original Article

Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model

verfasst von: Brittany L. Bunch, Krithika N. Kodumudi, Ellen Scott, Jennifer Morse, Amy Mackay Weber, Anders E. Berglund, Shari Pilon-Thomas, Joseph Markowitz

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Emm55 is a bacterial gene derived from Streptococcus pyogenes (S. pyogenes) that was cloned into a plasmid DNA vaccine (pAc/emm55). In this study, we investigated the anti-tumor efficacy of pAc/emm55 in a B16 murine melanoma model. Intralesional (IL) injections of pAc/emm55 significantly delayed tumor growth compared to the pAc/Empty group. There was a significant increase in the CD8⁺ T cells infiltrating into the tumors after pAc/emm55 treatment compared to the control group. In addition, we observed that IL injection of pAc/emm55 increased antigen-specific T cell infiltration into tumors. Depletion of CD4⁺ or CD8⁺ T cells abrogated the anti-tumor effect of pAc/emm55. Combination treatment of IL injection of pAc/emm55 with anti-PD-1 antibody significantly delayed tumor growth compared to either monotherapy. pAc/emm55 treatment combined with PD-1 blockade enhanced anti-tumor immune response and improved systemic anti-tumor immunity. Together, these strategies may lead to improvements in the treatment of patients with melanoma.

Nur mit Berechtigung zugänglich

Agarwala SS (2016) The role of intralesional therapies in melanoma. Oncology (Williston Park) 30(5):436–441

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788. https://doi.org/10.1200/JCO.2014.58.3377CrossRefPubMed

Lippey J, Bousounis R, Behrenbruch C, McKay B, Spillane J, Henderson MA et al (2016) Intralesional PV-10 for in-transit melanoma—a single-center experience. J Surg Oncol 114(3):380–384. https://doi.org/10.1002/jso.24311CrossRefPubMed

Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL et al (2016) Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 7(25):37893–37905. https://doi.org/10.18632/oncotarget.9247CrossRefPubMedPubMedCentral

Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA et al (2013) Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS ONE 8(7):e68561. https://doi.org/10.1371/journal.pone.0068561CrossRefPubMedPubMedCentral

Wiemann B, Starnes CO (1994) Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 64(3):529–564CrossRef

St Jean AT, Zhang M, Forbes NS (2008) Bacterial therapies: completing the cancer treatment toolbox. Curr Opin Biotechnol 19(5):511–517. https://doi.org/10.1016/j.copbio.2008.08.004CrossRefPubMedPubMedCentral

Bohle A, Schuller J, Knipper A, Hofstetter A (1990) Bacillus Calmette–Guerin treatment and vesicorenal reflux. Eur Urol 17(2):125–128CrossRef

Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS (2009) The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette–Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 28(3–4):345–353. https://doi.org/10.1007/s10555-009-9195-6CrossRefPubMed

10.

Kresowik TP, Griffith TS (2009) Bacillus Calmette–Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 1(2):281–288. https://doi.org/10.2217/1750743X.1.2.281CrossRefPubMedPubMedCentral

11.

de Jong SD, Basha G, Wilson KD, Kazem M, Cullis P, Jefferies W et al (2010) The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes. J Immunol 184(11):6092–6102. https://doi.org/10.4049/jimmunol.0802442CrossRefPubMed

12.

Chikh G, de Jong SD, Sekirov L, Raney SG, Kazem M, Wilson KD et al (2009) Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol 21(7):757–767. https://doi.org/10.1093/intimm/dxp044CrossRefPubMed

13.

Mahfouz M, Hashimoto W, Das Gupta TK, Chakrabarty AM (2007) Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy. Plasmid 57(1):4–17. https://doi.org/10.1016/j.plasmid.2006.11.001CrossRefPubMed

14.

Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mule JJ, Riker AI (2006) Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29(4):381–387. https://doi.org/10.1097/01.cji.0000199199.20717.67CrossRefPubMed

15.

Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, Nilsson UW et al (2010) Rational design of immunostimulatory siRNAs. Mol Ther 18(4):785–795. https://doi.org/10.1038/mt.2010.4CrossRefPubMedPubMedCentral

16.

Li K, Qu S, Chen X, Wu Q, Shi M (2017) Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways. Int J Mol Sci. https://doi.org/10.3390/ijms18020404CrossRefPubMedPubMedCentral

17.

Shi M, Chen X, Ye K, Yao Y, Li Y (2016) Application potential of toll-like receptors in cancer immunotherapy: systematic review. Medicine (Baltimore) 95(25):e3951. https://doi.org/10.1097/MD.0000000000003951CrossRef

18.

Bendelac A, Medzhitov R (2002) Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 195(5):F19–23. https://doi.org/10.1084/jem.20020073CrossRefPubMedPubMedCentral

19.

Krieg AM (2003) CpG motifs: the active ingredient in bacterial extracts? Nat Med 9(7):831–835. https://doi.org/10.1038/nm0703-831CrossRefPubMed

20.

Ramiya VK, Jerald MM, Lawman PD, Lawman MJ (2014) Autologous tumor cells engineered to express bacterial antigens. Methods Mol Biol 1139:243–257. https://doi.org/10.1007/978-1-4939-0345-0_21CrossRefPubMed

21.

Glikin GC, Finocchiaro LM (2014) Clinical trials of immunogene therapy for spontaneous tumors in companion animals. Sci World J 2014:718520. https://doi.org/10.1155/2014/718520CrossRef

22.

Brown EL, Ramiya VK, Wright CA, Jerald MM, Via AD, Kuppala VN, Hazell WS, Lawman PD, Lawman MJ (2014) Treatment of metastatic equine melanoma with a plasmid DNA vaccine encoding Streptococcus Pyogenes EMM55 protein. J Equine Vet Sci 34:704–708. https://doi.org/10.1016/j.jevs.2013.11.012CrossRef

23.

Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S (2016) Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy. PLoS ONE 11(4):e0153053. https://doi.org/10.1371/journal.pone.0153053CrossRefPubMedPubMedCentral

24.

Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S (2012) Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189(11):5147–5154. https://doi.org/10.4049/jimmunol.1200274CrossRefPubMedPubMedCentral

25.

Vohra N, Verhaegen M, Martin L, Mackay A, Pilon-Thomas S (2010) TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model. Cancer Immunol Immunother 59(5):729–736. https://doi.org/10.1007/s00262-009-0793-5CrossRefPubMedPubMedCentral

26.

Pilon-Thomas S, Nelson N, Vohra N, Jerald M, Pendleton L, Szekeres K et al (2011) Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function. PLoS ONE 6(11):e27729. https://doi.org/10.1371/journal.pone.0027729CrossRefPubMedPubMedCentral

27.

Kotera Y, Shimizu K, Mule JJ (2001) Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61(22):8105–8109PubMed

28.

Ibrahim-Hashim A, Abrahams D, Enriquez-Navas PM, Luddy K, Gatenby RA, Gillies RJ (2017) Tris-base buffer: a promising new inhibitor for cancer progression and metastasis. Cancer Med 6(7):1720–1729. https://doi.org/10.1002/cam4.1032CrossRefPubMedPubMedCentral

29.

Elso CM, Roberts LJ, Smyth GK, Thomson RJ, Baldwin TM, Foote SJ, Handman E (2004) Leishmaniasis host response loci (lmr13) modify disease severity through a Th1/Th2-independent pathway. Genes Immun 5(2):93–100. https://doi.org/10.1038/sj.gene.6364042CrossRefPubMed

30.

Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17(3):718–730. https://doi.org/10.1245/s10434-009-0809-6CrossRefPubMed

31.

Maletzki C, Linnebacher M, Kreikemeyer B, Emmrich J (2008) Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 57(4):483–491. https://doi.org/10.1136/gut.2007.125419CrossRefPubMed

32.

Schetters STT, Jong WSP, Horrevorts SK, Kruijssen LJW, Engels S, Stolk D, Daleke-Schermerhorn MH, Garcia-Vallejo J, Houben D, Unger WWJ, den Haan JMM, Luirink J, van Kooyk Y (2019) Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8+ T cells. Acta Biomater. https://doi.org/10.1016/j.actbio.2019.04.033CrossRefPubMed

33.

Kim WS, Jung ID, Kim JS, Kim HM, Kwon KW, Park YM, Shin SJ (2018) Mycobacterium tuberculosis GrpE, a heat-shock stress responsive chaperone, promotes Th1-biased T cell immune response via TLR4-mediated activation of dendritic cells. Front Cell Infect Microbiol 27(8):95. https://doi.org/10.3389/fcimb.2018.00095CrossRef

34.

Takeda Y, Azuma M, Funami K, Shime H, Matsumoto M, Seya T (2018) Type I interferon-independent dendritic cell priming and antitumor T cell activation induced by a mycoplasma fermentans lipopeptide. Front Immunol 14(9):496. https://doi.org/10.3389/fimmu.2018.00496CrossRef

35.

Friedrich C, Mamareli P, Thiemann S, Kruse F, Wang Z, Holzmann B, Strowig T, Sparwasser T, Lochner M (2017) MyD88 signaling in dendritic cells and the intestinal epithelium controls immunity against intestinal infection with C. rodentium. PLoS Pathog 13(5):e1006357. https://doi.org/10.1371/journal.ppat.1006357CrossRefPubMedPubMedCentral

36.

Pilon-Thomas S, Mackay A, Vohra N, Mule JJ (2010) Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 184(7):3442–3449. https://doi.org/10.4049/jimmunol.0904114CrossRefPubMedPubMedCentral

37.

Ozgun A, Sondak VK, Markowitz J (2016) Resistance patterns to anti-PD-1 therapy in metastatic melanoma. Chin Clin Oncol 5(6):75. https://doi.org/10.21037/cco.2016.08.01CrossRefPubMedPubMedCentral

38.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918. https://doi.org/10.1016/S1470-2045(15)00083-2CrossRefPubMed

39.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384. https://doi.org/10.1016/S1470-2045(15)70076-8CrossRefPubMed

40.

Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL et al (2017) A Genetically modified attenuated listeria vaccine expressing HPV16 E7 Kill tumor cells in direct and antigen-specific manner. Front Cell Infect Microbiol 7:279. https://doi.org/10.3389/fcimb.2017.00279CrossRefPubMedPubMedCentral

41.

Markowitz J, Kodumudi K, De Aquino DB, Sondak VK, Pilon-Thomas S (2019) Trial in progress: First in human Phase I study using a plasmid DNA coding for Emm55 streptococcal antigen (IFx-Hu2.0) in patients with unresectable stage III or stage IV cutaneous melanoma [abstract]. Cancer Res 79(13 Suppl):Abstract nr CT119

Titel: Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model
verfasst von: Brittany L. Bunch
Krithika N. Kodumudi
Ellen Scott
Jennifer Morse
Amy Mackay Weber
Anders E. Berglund
Shari Pilon-Thomas
Joseph Markowitz
Publikationsdatum: 18.06.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02634-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab

Current trends in cancer immunotherapy: a literature-mining analysis

Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy

Increased IL-10+CD206+CD14+M2-like macrophages in alveolar lavage fluid of patients with small cell lung cancer

Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer

Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie